Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 100

Results For "FY"

2472 News Found

EMA moves to cut animal testing with “virtual control groups” in preclinical research
Policy | April 03, 2026

EMA moves to cut animal testing with “virtual control groups” in preclinical research

The approach, which could significantly reduce the number of rats used in certain dose-range finding studies


D2C nutrition brand BeastLife raises Rs 20 crore at Rs 320 crore valuation from GVFL and Equentis
News | April 02, 2026

D2C nutrition brand BeastLife raises Rs 20 crore at Rs 320 crore valuation from GVFL and Equentis

The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years


Alembic Pharmaceuticals partners with Enthral.ai for learning and training management of its 9000+ learners
News | April 02, 2026

Alembic Pharmaceuticals partners with Enthral.ai for learning and training management of its 9000+ learners

Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows


Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027
Biotech | April 02, 2026

Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027

As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million


Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients
News | April 02, 2026

Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients

Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina


Middle East disruption hits thousands of global clinical trials, Phesi warns
Clinical Trials | April 02, 2026

Middle East disruption hits thousands of global clinical trials, Phesi warns

The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment


Rusan unveils APOSAN 3ml multi-dose pen
News | April 01, 2026

Rusan unveils APOSAN 3ml multi-dose pen

The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes


Bristol Myers Squibb expands groundbreaking program to close faps in multiple myeloma care
News | April 01, 2026

Bristol Myers Squibb expands groundbreaking program to close faps in multiple myeloma care

The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners


Agilent bags FDA nod for key cancer diagnostic
News | March 31, 2026

Agilent bags FDA nod for key cancer diagnostic

The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen


Philanthropist Ludacris teams up with One A Day to make health simple
Healthcare | March 29, 2026

Philanthropist Ludacris teams up with One A Day to make health simple

The campaign highlights a straightforward, achievable approach to health, proving that supporting your wellness doesn’t have to be complicated